9a178e71-figure-01 (Image 1)
Irinotecan Hydrochloride Injection, Solution
Product Images NDC 45963-614
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 45963-614). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
9a178e71-figure-02 (Image 2)
9a178e71-figure-03 (Image 3)
1 (Image 4)
Image 5
This dataset includes information on the comparison between Irinotecan and 5-Fluorouracil (5-FU), with a sample size of 127 and 129 patients respectively. The median follow-up period is 15 months, with median survival rates of 108 months for Irinotecan and 85 months for 5-FU. The probability of survival for Irinotecan is reported as 0.44, with a p-value of 0.035 based on a log-rank test analysis.*
Image 6
This is a product label for Irinotecan Hydrochloride Injection, USP. It provides information about the dosage (40 mg/2 ml), dilution requirement, and warnings for intravenous use only as it is a cytotoxic agent. The text also mentions that the vial stopper is sterile, non-pyrogenic, and preservative-free. The medication is manufactured in Romania and by Teva Pharmaceuticals. It is important to read the entire label before use and follow dosage and administration instructions provided in the package insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
